Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
Children who receive the chickenpox (varicella) vaccine are significantly less likely to contract shingles, according to a new study led by researchers at the Kaiser Permanente Center for Health Research published today in the journal Pediatrics.
More Americans are being diagnosed with eye complications of shingles, but older adults can call the shots on whether they are protected from the painful rash that can cost them their eyesight.
A new systematic review provides a succinct summary of the scientific evidence for and/or against causal associations for 47 adverse events following immunization.
NASA has come up with a warning about herpes zoster or shingles being activated among crew aboard the Space Shuttle and the International Space Station missions. The problem was highlighted in a study that appeared in the latest issue of the journal Frontiers in Microbiology.
Stroke risk increased significantly in the days, weeks and months after shingles appeared, despite use of the shingles vaccine and antiviral therapy to treat it, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
People newly diagnosed with cancer, particularly blood cancers, and those treated with chemotherapy have a greater risk of developing shingles, according to a new study in the Journal of Infectious Diseases.
A systematic review of clinical studies involving more than two million patients aged 50 years and older suggests a recently released shingles vaccine was far more successful in preventing the painful condition compared to the older vaccine - but also carried greater risk of side-effects.
AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.
A recent publication from The American Journal of Managed Care, the leading peer-reviewed journal dedicated to issues in managed care, addresses the role of community pharmacies in boosting adult vaccination rates in the United States.
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication.
Anyone who has had chickenpox or the chickenpox vaccine is at risk for the painful skin condition herpes zoster, more commonly known as shingles. Both diseases are caused by the varicella-zoster virus, which stays in the body after chickenpox clears and may reactivate later in life.
Last month a U.S. Food and Drug Administration (FDA) advisory panel had voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline’s Shingrix.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline’s Shingrix is on its way to FDA approval.